Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $65.3 million.

  • Phathom Pharmaceuticals' Accumulated Expenses rose 82.75% to $65.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.3 million, marking a year-over-year increase of 82.75%. This contributed to the annual value of $53.2 million for FY2024, which is 209.54% up from last year.
  • As of Q3 2025, Phathom Pharmaceuticals' Accumulated Expenses stood at $65.3 million, which was up 1.64% from $64.3 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Accumulated Expenses' 5-year high stood at $65.3 million during Q3 2025, with a 5-year trough of $7.6 million in Q1 2022.
  • In the last 3 years, Phathom Pharmaceuticals' Accumulated Expenses had a median value of $27.3 million in 2024 and averaged $32.7 million.
  • Data for Phathom Pharmaceuticals' Accumulated Expenses shows a peak YoY skyrocketed of 209.54% (in 2024) over the last 5 years.
  • Phathom Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $14.7 million in 2022, then grew by 17.16% to $17.2 million in 2023, then surged by 209.54% to $53.2 million in 2024, then skyrocketed by 82.75% to $65.3 million in 2025.
  • Its Accumulated Expenses stands at $65.3 million for Q3 2025, versus $64.3 million for Q2 2025 and $43.0 million for Q1 2025.